[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
November 3, 1999

First Antibacterial for VREF

Author Affiliations

Not Available

Not Available

JAMA. 1999;282(17):1613. doi:10.1001/jama.282.17.1613-JFD90009-2-1

The FDA has approved Synercid (Rhone-Poulenc Rorer, Collegeville, Pa), the first antimicrobial drug to treat infections associated with vancomycin-resistant Enterococcus faecium (VREF) bacteremia. Synercid, a combination of quinupristin and dalfopristin, also received approval for the treatment of complicated skin and skin structure (SST) infections (such as cellulitis/erysipelas, postoperative infections, and traumatic wound infections) caused by methicillin-susceptible Staphylococcus aureus and Streptococcus pyogenes.

First Page Preview View Large
First page PDF preview
First page PDF preview